Aquestive Therapeutics, Inc. (AQST)
NASDAQ: AQST · Real-Time Price · USD
4.950
+0.270 (5.77%)
At close: Oct 4, 2024, 4:00 PM
4.940
-0.010 (-0.20%)
After-hours: Oct 4, 2024, 7:16 PM EDT

Company Description

Aquestive Therapeutics, Inc. operates as a pharmaceutical company in the United States and internationally.

The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder.

Its proprietary product candidates comprise Libervant, a buccal soluble film formulation of diazepam for the treatment of seizures; KYNMOBI, a sublingual film formulation of apomorphine for the treatment of episodic off-periods in Parkinson’s disease; and Exservan, an oral soluble film formulation of riluzole for the treatment of amyotrophic lateral sclerosis.

The company’s proprietary pipeline of complex molecule product includes AQST-108, a sublingual film formulation delivering systemic epinephrine for the treatment of conditions other than anaphylaxis; and Anaphylm, an epinephrine sublingual film for the emergency treatment of allergic reactions, including anaphylaxis.

In addition, it develops Adrenaverse, an epinephrine prodrug platform. The company was incorporated in 2004 and is headquartered in Warren, New Jersey.

Aquestive Therapeutics, Inc.
Aquestive Therapeutics logo
Country United States
Founded 2004
IPO Date Jul 25, 2018
Industry Drug Manufacturers - Specialty & Generic
Sector Healthcare
Employees 135
CEO Daniel Barber

Contact Details

Address:
30 Technology Drive
Warren, New Jersey 07059
United States
Phone (908) 941-1900
Website aquestive.com

Stock Details

Ticker Symbol AQST
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001398733
CUSIP Number 03843E104
ISIN Number US03843E1047
Employer ID 20-8623253
SIC Code 2834

Key Executives

Name Position
Daniel Barber Chief Executive Officer, President and Director
A. Ernest Toth Jr. Chief Financial Officer
Lori J. Braender BSBA, Esq., J.D. General Counsel, Chief Compliance Officer and Corporate Secretary
Cassie Jung Chief Operating Officer
Alexander Mark Schobel Chief Innovation and Technology Officer
Dr. Stephen Wargacki Ph.D. Chief Science Officer
Sherry Korczynski Senior Vice President of Sales and Marketing
Peter E. Boyd Senior Vice President of Information Technology and Human Resources
Dr. Gary H. Slatko M.D., MBA Chief Medical Officer
Dr. Carl N. Kraus M.D. Chief Medical Officer

Latest SEC Filings

Date Type Title
Sep 27, 2024 8-K Current Report
Sep 9, 2024 8-K Current Report
Aug 14, 2024 8-K Current Report
Aug 6, 2024 10-Q Quarterly Report
Aug 6, 2024 8-K Current Report
Jul 25, 2024 8-K Current Report
Jun 21, 2024 8-K Current Report
Jun 7, 2024 8-K Current Report
Jun 6, 2024 8-K Current Report
May 8, 2024 8-K Current Report